Italia markets closed

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,3100+0,0200 (+1,55%)
Alla chiusura: 04:00PM EDT
1,3100 0,00 (0,00%)
Dopo ore: 04:31PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,2900
Aperto1,2700
Denaro1,2300 x 900
Lettera1,3200 x 1100
Min-Max giorno1,2300 - 1,3200
Intervallo di 52 settimane1,2300 - 14,4900
Volume240.730
Media Volume1.327.983
Capitalizzazione81,157M
Beta (5 anni mensile)0,49
Rapporto PE (ttm)N/D
EPS (ttm)-1,4500
Prossima data utili30 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A6,50
  • GlobeNewswire

    Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023

    DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2022 before the market opens on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dia

  • GlobeNewswire

    Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition

    DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into a Settlement Agreement (the “Settlement Agreement”) with the former CartiHeal shareholders (the “CartiHeal Sellers”) regarding the Company’s obligations under the amended Option and Equity Purchase Agreement for its prior acquisition of CartiHeal (the “Amended Acquisition Agreement”). The Settlemen

  • GlobeNewswire

    Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m. PT (8:15 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 10, 2023. About BioventusBio